About us

Circassia is a specialty pharmaceutical company focused on respiratory disease. Our growing commercial organization promotes our innovative asthma management products directly to specialist physicians in a number of key markets, and we market the chronic obstructive pulmonary disease (COPD) product Tudorza® in the United States. Recently, we significantly expanded our commercial platform in China, launching our own direct sales team, and in March 2019 received US approval for our COPD combination treatment Duaklir®. We are working to expand our portfolio further through in-licensing, partnering or acquisition, and recently we acquired the commercial rights to the ventilator-compatible nitric oxide product AirNOvent* in the US and China.

Our asthma management products

Our market-leading NIOX® products are used by specialists around the world to aid asthma diagnosis and management. We sell NIOX® direct in the United States, United Kingdom, China and Germany. Our NIOX® products are also supplied in many other countries through our international network of partners.

Our US commercial collaboration

We collaborate with AstraZeneca in the United States, where we have the commercial rights to the COPD product Tudorza®, which we promote through our dedicated sales force. We also have the US commercial rights to Duaklir®, which we plan to launch in the second half of 2019 following its recent approval.

Our AirNOvent partnership

In early 2019, we acquired the exclusive commercial rights to ventilator-compatible nitric oxide product AirNOvent in the US and China from AIT Therapeutics Inc. AIT plans to submit the product for approval in the United States in the coming months for use in the treatment of hypoxic respiratory failure associated with persistent pulmonary hypertension of the newborn.

Our history

Circassia was established in 2006, and in March 2014 we completed an initial public offering on the London Stock Exchange.  In June 2015, we completed the acquisition of NIOX® as part of our strategy to independently commercialize our products and broaden our portfolio, and in April 2017 we established our commercial collaboration with AstraZeneca in the United States. In January 2019, we acquired the commercial rights to AirNOvent in the US and China, and in February 2019 we completed the move of the Company’s shares to AIM where they are quoted under CIR.

*AirNOvent is not an approved name for the product and may not be the final name submitted for approval.